ArticleJTCVS open2025
Long-term survival for preoperative versus postoperative treatment of N2 lung cancer: The importance of complete adjuvant therapy for occult N2 disease.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Unsuspected (defined here as occult) N2-positive lung cancer impacts overall survival (OS), and treatment patterns likely influence outcomes. We aimed to evaluate factors that could improve the long-term outcomes of patients with occult N2 disease compared to biopsy-proven, pre-resectional N2 disease. Methods: Our institutional prospective database was queried for N2 non-small cell lung cancer (NSCLC) at presentation (biopsy-proven) prior to surgical resection or postoperatively diagnosed N2 (occult N2), excluding stage IV disease or patients with insufficient follow-up. In occult N2 group, postoperative therapy was stratified into complete (≥3 cycles), incomplete (1-2 cycles), or no adjuvant treatment. Propensity score weighting adjusted for age, comorbidities, tumor size, and N2 involvement. Kaplan-Meier analysis assessed 5-year overalls survival (OS). Results: Between 2006-2023, 483 patients met inclusion criteria, stratified into 325 patients (67.2%) with biopsy-proven N2 and 158 (32.8%) with occult N2. The biopsy-proven N2 group primarily received neoadjuvant therapy (chemo/chemoimmunotherapy ± radiation). In the occult N2 group, 86 patients (54.4%) received full-dose adjuvant therapy, 31 (19.6%) received incomplete adjuvant therapy, and 41 (26%) received no adjuvant therapy. After propensity score weighting, the occult N2 group had significantly lower OS ( Conclusions: Patients with occult N2 treated with adjuvant treatment may achieve improved survival rates compared to those not fully treated. Neoadjuvant treatment is optimal to ensure delivery of therapy as prescribed, and thus every effort should be made to identify N2 disease prior to resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.